NCT06790602 2026-04-09
SWITCH
University of California, San Diego
Phase 2 Recruiting
Clinical Trials
11 trialsNCT07404332 2026-02-11
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
University of Iowa
Phase 1 Not yet recruiting
NCT07346196 2026-01-20
A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
University of Chicago
Phase 2 Not yet recruiting
NCT05259709 2025-09-11
A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab
Regeneron Pharmaceuticals
Phase 1 Recruiting
NCT03871348 2025-09-10
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Terminated
NCT04706715 2025-05-31
LAG3 PET Imaging in Advanced Solid Tumors
University Medical Center Groningen
Phase 1/2 Active not recruiting
NCT04050436 2025-01-27
CERPASS
Replimune Inc.
Phase 2 Active not recruiting
NCT05878288 2024-11-21
DISCERN
Peter MacCallum Cancer Centre, Australia
Phase 2 Active not recruiting
NCT03005782 2024-05-01
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Regeneron Pharmaceuticals
Phase 1 Completed
NCT04729725 2023-08-14
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05302297 2022-12-13
TOSCA
Sanofi
Completed